Premature ovarian Insufficiency

The ovary is a female reproductive organ with two intrinsically important physiological functions. First, the ovary is responsible for follicle formation, differentiation, and the release of mature oocytes for fertilization. Second, it is responsible for synthesizing and secreting sex steroid hormones (i.e., estrogens, progestins, and androgens) required to sustain follicle development, fertility, normal menstrual/estrous cyclicity, and pregnancy, thus regulating reproduction. The phrase "ovarian reserve" refers to the potential functionality of the ovaries, indicating the amount and quality of follicles and oocytes, and is used to determine the stage of reproductive aging. Premature ovarian insufficiency (POI) is a clinical disease characterized by insufficient ovarian sex hormones and reduced ovarian reserve, which together contribute to a rapid reduction in ovarian function and an early onset of menopause.

POI occurs through two major mechanisms: follicle dysfunction and follicle depletion. Several factors are linked to POI, including infections, iatrogenic surgeries, autoimmune and metabolic disorders, and environmental toxicants. Environmental factors appear to be significant contributors to ovarian reserve or early menopause, either throughout the prenatal period or during adult life.  Follicle depletion means that there are no primordial follicles left in the ovary. This condition can be caused by several factors, including failure to produce an adequate initial pool of primordial follicles during gestation, rapid follicle turnover, or autoimmune or toxic destruction of follicles. POI is a medical condition in which ovarian follicles become exhausted and no longer function normally as reproductive and endocrine organs in women under the age of 40. It is characterized by low ovarian sex hormone levels and a reduced number of ovarian follicles, hastening the onset of menopause. This condition frequently results in subfertility or infertility due to hypoestrogenism, which causes menstrual abnormalities and pregnancy failures. Approximately 1% of women under the age of 40 experience POI.

OECD 416 two generation reproductive toxicity study (2001): Weigh each ovary separately. qualitative analysis of the F0 generation's ovaries to identify the depletion of primordial follicles. Counting how many F1 primordial follicles are there in ovaries using quantitative evaluation (may be paired with small developing follicles). Although not required, the selection of ovarian portions, quantity of animals, and section process must all be statistically reliable. 

OECD 443 (Extended One-Generation Reproductive Toxicity Study) 2011: To screen for effects that might arise from prenatal and postnatal chemical exposure and to assess particular life phases that are not addressed by other kinds of toxicity testing. Examining the ovaries histologically is highlighted in the guideline for determining follicle numbers. This includes: The ovaries of females (parental generation and offspring, if relevant) are taken during necropsy and kept in an appropriate fixative (such as formalin or Bouin's solution). Primordial, primary, secondary, and antral follicles are among the several follicle stages that can be examined under a microscope by sectioning and staining ovarian tissue. Follicle counts are done to identify any possible harmful effects on folliculogenesis that may affect reproductive health and fertility. 

U.S. FDA Redbook 2000 IV.C.9.a Guidelines for reproduction studies (2000): Ovarian qualitative analysis to identify degradation of primordial follicles. Quantitative analysis is used to ascertain how many primordial follicles are present in the high dose and F0 and F1 control ovaries. The recommended method is to cut each ovary into five parts, separated by at least 100 μ from the inner third. Count  amount of primordial follicles in every part of the ten sections. In comparison to control ovaries, the examination should also verify whether developing follicles and corpora lutea are present.

The follicular pool in humans cannot be directly counted in vivo. Surrogate markers are employed instead. Anti-Müllerian hormone (AMH) is the most well-established biomarker for estimating the follicular pool.

This AO is relevant exclusively to females, as it concerns biological processes specific to the ovaries and follicle development. It covers the prenatal, postnatal, and adult stages, which are key periods for follicle formation, survival, and depletion. In humans, it is most applicable to women below 40 years of age, since ovarian function typically begins to decline naturally after this age. The AO is based on data from humans, mice, rats, and fish, but due to shared reproductive mechanisms, it is likely relevant across vertebrate species.

The AO, Premature ovarian insufficiency (POI) lies its emphasis on ovarian follicle counts as a key factor in assessing reproductive health. While currently optional in OECD test guidelines, the AOP underscores the strong link between follicle numbers and fertility, as well as their association with conditions like POI and early menopause. Regulatory frameworks should prioritize follicle depletion as a critical biomarker, not only for evaluating reproductive endpoints but also for advancing understanding of infertility-related disorders. Integrating follicle count assessments into mandatory criteria could improve the identification of reproductive toxicants and ensure better protection of women's reproductive health in regulatory decisions.

1. Kerr JB, Myers M, Anderson RA. The dynamics of the primordial follicle reserve. Reproduction. 2013;146(6):R205-15.
2. Hummitzsch K, Irving-Rodgers HF, Hatzirodos N, Bonner W, Sabatier L, Reinhardt DP, et al. A New Model of Development of the Mammalian Ovary and Follicles. PLOS ONE. 2013;8(2):e55578
3. Monniaux D, Cadoret V, Clément F, Tran R, Elis S, Fabre S, et al. Folliculogenesis2018.
4. Albamonte MI, Albamonte MS, Bou-Khair RM, Zuccardi L, Vitullo AD. The ovarian germinal reserve and apoptosis-related proteins in the infant and adolescent human ovary. J Ovarian Res. 2019;12(1):22.
5. Aitken RJ, Findlay JK, Hutt KJ, Kerr JB. Apoptosis in the germ line. Reproduction. 2011;141(2):139-50.
6. Rahman R, Panay N. Diagnosis and management of premature ovarian insufficiency. Best Pract Res Clin Endocrinol Metab. 2021;35(6):101600.
7. Chon SJ, Umair Z, Yoon MS. Premature Ovarian Insufficiency: Past, Present, and Future. Front Cell Dev Biol. 2021;9:672890.
8. Ye X, Pan W, Li C, Ma X, Yin S, Zhou J, Liu J. Exposure to polycyclic aromatic hydrocarbons and risk for premature ovarian failure and reproductive hormones imbalance. J Environ Sci (China). 2020;91:1-9.
9. https://www.oecd-ilibrary.org/environment/test-no-416-two-generation-reproduction-toxicity_9789264070868-enTest No. 416: Two-Generation Reproduction Toxicity. OECD Guidelines for the Testing of Chemicals, Section 42001.

10.  https://www.oecd-ilibrary.org/environment/test-no-443-extended-one-generation-reproductive-toxicity-study_9789264185371-en. Test No. 443: Extended One-Generation Reproductive Toxicity Study. OECD Guidelines for the Testing of Chemicals2018.

11. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/redbook-2000-ivc9aguidelines-reproduction-studies. GUIDANCE DOCUMENT, Redbook 2000: IV.C.9.a.Guidelines for Reproduction Studies. 2000.

12. Broer SL, Broekmans FJ, Laven JS, Fauser BC. Anti-Müllerian hormone: ovarian reserve testing and its potential clinical implications. Hum Reprod Update. 2014;20(5):688-701.